Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DBT009
MIFTS: 67

Diabetes Mellitus

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diabetes Mellitus

About this section

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 38 12 76 29 55 6 44 15 73
Diabetes 43 3 15 40 73

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases
Anatomical: Endocrine diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 35 250
MeSH 44 D003920
NCIt 50 C2985
SNOMED-CT 68 73211009
Sources

Summaries for Diabetes Mellitus

About this section
MedlinePlus : 43 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to diabetes mellitus, permanent neonatal and diabetes mellitus, transient neonatal, 1, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Voltage-Gated Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Linagliptin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and kidney.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

Novus Biologicals : 56 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 76 Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders in which... more...

Sources

Related Diseases for Diabetes Mellitus

About this section

Diseases in the Diabetes Mellitus family:

Diabetes Mellitus, Congenital Autoimmune Type 1 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 3 Type 1 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 5 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 11
Type 1 Diabetes Mellitus 12 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 17
Type 1 Diabetes Mellitus 18

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2201)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, permanent neonatal 35.0 ABCC8 INS KCNJ11
2 diabetes mellitus, transient neonatal, 1 35.0 ABCC8 INS KCNJ11
3 diabetes mellitus, noninsulin-dependent 34.9 ABCC8 CDKN2B-AS1 HNF4A INS KCNJ11 PVT1
4 neonatal diabetes mellitus 34.8 ABCC8 INS KCNJ11
5 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 34.7 ABCC8 KCNJ11
6 insulinomatosis and diabetes mellitus 34.4 ABCC8 INS
7 maturity-onset diabetes of the young, type 13 34.2 ABCC8 HNF4A INS KCNJ11
8 maturity-onset diabetes of the young 34.2 ABCC8 HNF4A INS KCNJ11
9 maturity-onset diabetes of the young, type 1 34.1 ABCC8 HNF4A INS KCNJ11
10 gestational diabetes 34.1 HNF4A INS KCNJ11
11 maturity-onset diabetes of the young, type 10 34.0 INS KCNJ11
12 thiamine-responsive megaloblastic anemia syndrome 33.8 ABCC8 INS KCNJ11
13 microvascular complications of diabetes 3 32.7 INS MALAT1 PVT1
14 maturity-onset diabetes of the young, type 2 32.5 HNF4A INS
15 abdominal obesity-metabolic syndrome 1 32.4 INS MEG3
16 hypoglycemia 32.0 ABCC8 INS KCNJ11
17 hyperglycemia 31.6 ABCC8 INS KCNJ11 MALAT1
18 hyperinsulinism 31.5 ABCC8 HNF4A INS KCNJ11
19 prostate disease 31.4 CDKN2B-AS1 MALAT1 MEG3
20 coronary heart disease 1 31.2 CDKN2B-AS1 INS MIR145 MIR155
21 nonalcoholic fatty liver disease 31.1 INS MIR132 MIR140
22 insulinoma 31.0 ABCC8 INS MEN1
23 monogenic diabetes 31.0 ABCC8 HNF4A INS KCNJ11
24 pancreatic agenesis 30.9 ABCC8 INS KCNJ11
25 acute insulin response 30.8 ABCC8 INS KCNJ11
26 hypertension, essential 30.7 CDKN2B-AS1 INS MEN1 MIR155
27 hyperinsulinemic hypoglycemia 30.7 ABCC8 HNF4A INS KCNJ11 MEN1
28 atherosclerosis susceptibility 30.6 CDKN2B-AS1 INS TUG1
29 glucose metabolism disease 30.4 ABCC8 INS KCNJ11
30 munchausen by proxy 30.2 ABCC8 KCNJ11
31 fanconi-bickel syndrome 30.0 ABCC8 INS
32 pancreas disease 29.9 ABCC8 INS KCNJ11
33 pancreatic ductal adenocarcinoma 29.9 MALAT1 MIR145 MIR155 MIR375 PVT1
34 kidney cancer 29.9 MALAT1 MEG3 PVT1
35 pancreatic endocrine carcinoma 29.8 INS MEG3
36 endometriosis 29.7 CDKN2B-AS1 MIR145 MIR99A
37 gastric cancer 29.6 CDKN2B-AS1 MALAT1 MEG3 MIR145 PVT1 TUG1
38 ovarian epithelial cancer 29.6 MALAT1 MEG3
39 diffuse large b-cell lymphoma 29.6 MIR145 MIR155 MIR99A
40 hirata disease 29.6 ABCC8 INS
41 lymphoma, hodgkin, classic 29.6 MIR140 MIR155 PVT1
42 pancreatic cancer 29.5 CDKN2B-AS1 MALAT1 MEG3 MEN1 MIR155 MIR375
43 dermatomyositis 29.5 MIR132 MIR155
44 melanoma 29.5 CDKN2B-AS1 MALAT1 MEG3 MIR140 PVT1
45 nasopharyngeal carcinoma 29.5 CDKN2B-AS1 MALAT1 MEG3 PVT1
46 gallbladder cancer 29.5 CDKN2B-AS1 MALAT1 MEG3 TUG1
47 breast cancer 29.4 CDKN2B-AS1 INS MALAT1 MEG3 MIR145 MIR155
48 bladder cancer 29.4 CDKN2B-AS1 MALAT1 MEG3 MIR145 MIR99A PVT1
49 hepatocellular carcinoma 29.4 CDKN2B-AS1 HNF4A MALAT1 MEG3 MIR132 MIR145
50 prostate cancer 29.4 CDKN2B-AS1 MALAT1 MEG3 MIR145 MIR375 MIR99A

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus
Sources

Symptoms & Phenotypes for Diabetes Mellitus

About this section

UMLS symptoms related to Diabetes Mellitus:


tremor, angina pectoris, equilibration disorder, symptoms
Sources

Drugs & Therapeutics for Diabetes Mellitus

About this section

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1082)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
3
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6
4
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137862-53-4 60846
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
9
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
10
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135062-02-1 65981
11
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 2,Phase 3 33069-62-4 36314
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
15
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
16
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
17
Calcium Carbonate Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 471-34-1
18
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21187-98-4 3475
19
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 204656-20-2 44147092
20
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 133107-64-9
21
Mineral oil Approved, Vet_approved Phase 4,Not Applicable 8042-47-5
22
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 5362032 40466924
23
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
24
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
25
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Not Applicable 163222-33-1 150311
26
Ticagrelor Approved Phase 4,Phase 3,Not Applicable 274693-27-5 9871419
27
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
28
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
29
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 113665-84-2, 120202-66-6 60606
30
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53608-75-6
31
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
32
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
33
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
34
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
35
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
36
rituximab Approved Phase 4,Phase 1,Phase 2 174722-31-7 10201696
37
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
38
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56180-94-0 441184
39
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 116094-23-6 16132418
40
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 10238-21-8 3488
41
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
42
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 124-94-7 31307
43
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
44
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
46
Basiliximab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 152923-56-3, 179045-86-4
47
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
48
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
49
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 87333-19-5 5362129
50
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 501-36-0 445154

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
2 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin
3 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
4 Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes Unknown status NCT00265746 Phase 4 Metformin
5 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
6 Preventing Recurrent Gestational Diabetes With Metformin Unknown status NCT02394158 Phase 4 Metformin;placebo
7 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4 Scilin®M30
8 The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes Unknown status NCT02307695 Phase 4 Saxagliptin;Insulin
9 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
10 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
11 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
12 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
13 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
14 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
15 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4 Repaglinide
16 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4 Metformin and Saxagliptin
17 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
18 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
19 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
20 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
21 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
22 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
23 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis Unknown status NCT02169570 Phase 4
24 Effect of Anti-diabetic Drugs on Glycemic Variability Unknown status NCT02925559 Phase 4 Dapagliflozin;Gliclazide MR
25 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
26 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
27 Glucometer and Mobile-phone Based Data Transfer System in Diabetes Unknown status NCT02769377 Phase 4
28 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
29 Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients Unknown status NCT00427271 Phase 4 aspirin
30 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
31 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
32 Intervention to Promote Weight Loss in Latinas At-risk for Diabetes Unknown status NCT02088034 Phase 4 Metformin Therapy
33 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
34 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
35 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
36 The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
37 How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? Unknown status NCT00749047 Phase 4 Pioglitazone
38 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
39 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
40 Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
41 A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria Unknown status NCT00843388 Phase 4 Spironolacton (hexalacton(R));placebo tablet
42 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4 Glucagon
43 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4 Angiotensin II receptor antagonists, Calcium channel blocker
44 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
45 Probiotics in Newly Recognized Type 1 Diabetes Unknown status NCT03032354 Phase 4 Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
46 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
47 Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
48 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
49 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4 rituximab
50 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: diabetes mellitus

Sources

Genetic Tests for Diabetes Mellitus

About this section

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29
Sources

Anatomical Context for Diabetes Mellitus

About this section

MalaCards organs/tissues related to Diabetes Mellitus:

41
Endothelial, Heart, Kidney, Testes, Liver, Bone, Pancreas
Sources

Publications for Diabetes Mellitus

About this section

Articles related to Diabetes Mellitus:

(show top 50) (show all 16078)
# Title Authors Year
1
Structural and functional damage to the hippocampal neurovascular unit in diabetes-related depression. ( 30531012 )
2019
2
Implementing and feasibility testing depression screening using the electronic medical record for patients with type 2 diabetes admitted to the hospital. ( 30534392 )
2019
3
Nephrogenic Diabetes Insipidus. ( 30454745 )
2019
4
Higher hemoglobin A1C and atherogenic lipoprotein profiles in children and adolescents with type 2 diabetes mellitus. ( 30547005 )
2019
5
Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; Impact of Nrf2/HO-1 and JAK/STAT pathways. ( 30551471 )
2019
6
Role of medicinal plants in the management of diabetes mellitus: a review. ( 30555770 )
2019
7
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. ( 30487058 )
2019
8
Glutamine and type 1 diabetes mellitus: is there a role in glycemic control? ( 30461450 )
2019
9
Inhibitory effect of silibinin on Amadori-albumin in diabetes mellitus: A multi-spectroscopic and biochemical approach. ( 30399482 )
2019
10
Differences in skin blood flow oscillations between the plantar and dorsal foot in people with diabetes mellitus and peripheral neuropathy. ( 30414870 )
2019
11
Pre, peri and posttransplant diabetes mellitus. ( 30418189 )
2019
12
Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. ( 30391067 )
2019
13
Stem cells in the treatment of diabetes mellitus - Focus on mesenchymal stem cells. ( 30342065 )
2019
14
A randomized controlled trial of a web-based education intervention for women with gestational diabetes mellitus. ( 30343264 )
2019
15
Punicic acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management. ( 30317607 )
2019
16
ERα and/or ERβ activation ameliorates cognitive impairment, neurogenesis and apoptosis in type 2 diabetes mellitus mice. ( 30201537 )
2019
17
Evolution of type 2 diabetes mellitus treatment approaches. ( 30204296 )
2019
18
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. ( 30145806 )
2019
19
Expression of inflammasome complex mRNA and its targeted microRNA in type 2 diabetes mellitus: A possible predictor of the severity of diabetic nephropathy. ( 30151904 )
2019
20
Association between early introduction of fruit juice during infancy and childhood consumption of sweet-tasting foods and beverages among children exposed and unexposed to gestational diabetes mellitus in utero. ( 30171916 )
2019
21
Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus. ( 30176239 )
2019
22
Pregnancy and post-partum muscle and cerebral oxygenation during intermittent exercise in gestational diabetes: A pilot study. ( 30468984 )
2019
23
Interactions among insulin resistance, inflammation factors, obesity-related gene polymorphisms, environmental risk factors, and diet in the development of gestational diabetes mellitus. ( 29519182 )
2019
24
Maternal Dyslipidaemia in Pregnancy with Gestational Diabetes Mellitus: Possible Impact on Foetoplacental Vascular Function and Lipoproteins in the Neonatal Circulation. ( 29149816 )
2019
25
Impact of an electronic medical record reminder on hepatitis B vaccine initiation and completion rates among insured adults with diabetes mellitus. ( 29958736 )
2019
26
Type 1 diabetes alters ischemia-induced gene expression. ( 30555789 )
2019
27
Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: Erratum. ( 30531249 )
2019
28
Long-term cost-effectiveness of a Patient Empowerment Programme for type 2 diabetes mellitus in primary care. ( 30058268 )
2019
29
Toll-Like Receptor 2 (TLR-2) Gene Polymorphisms in Type 2 Diabetes Mellitus. ( 30124003 )
2019
30
The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial ( 29803203 )
2019
31
Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models. ( 30473057 )
2019
32
Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. ( 30551545 )
2019
33
In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. ( 30551359 )
2019
34
Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes. ( 30551370 )
2019
35
Azadirachta indica inhibits key enzyme linked to type 2 diabetes in vitro, abates oxidative hepatic injury and enhances muscle glucose uptake ex vivo. ( 30551526 )
2019
36
Novel cancer therapies and their association with diabetes. ( 30532995 )
2019
37
Medication belief as correlate of medication adherence among patients with diabetes in Edo State, Nigeria. ( 30534409 )
2019
38
The clinical utility of the AUSDRISK tool in assessing change in type 2 diabetes risk in overweight/obese volunteers undertaking a healthy lifestyle intervention. ( 30534513 )
2019
39
Monosodium Glutamate (MSG)-Induced Animal Model of Type 2 Diabetes. ( 30535681 )
2019
40
An Analysis of the Intracellular Signal Transduction of Peripheral Blood Leukocytes in Animal Models of Diabetes Using Flow Cytometry. ( 30535695 )
2019
41
Characterization of the db/db Mouse Model of Type 2 Diabetes. ( 30535696 )
2019
42
Characterization of the Goto-Kakizaki (GK) Rat Model of Type 2 Diabetes. ( 30535697 )
2019
43
Method Protocols for Metabolic and Functional Analysis of the BRIN-BD11 β-Cell Line: A Preclinical Model for Type 2 Diabetes. ( 30535710 )
2019
44
Suppression of Oxygen Radicals Protects Diabetic Endothelium Damage and Tissue Perfusion in a Streptozotocin-Induced Diabetes Rodent Model. ( 30540602 )
2019
45
A simple to implement and low-cost supervised walking programme in highly motivated individuals with or at risk for type 2 diabetes: An observational study with a pre-post design. ( 30510891 )
2019
46
Altered blood rheology and impaired pressure-induced cutaneous vasodilation in a mouse model of combined type 2 diabetes and sickle cell trait. ( 30513282 )
2019
47
TGF-beta/TGF-beta RII/CLC-3 axis promotes cognitive disorders in diabetes. ( 30468668 )
2019
48
Emerging role of Unfolded Protein Response (UPR) mediated proteotoxic apoptosis in diabetes. ( 30471281 )
2019
49
Validation of the Arabic and Tunisian Arabic version of the KINDL questionnaires for children with diabetes type 1. ( 30481145 )
2019
50
A Data-Driven Personalized Model of Glucose Dynamics Taking Account of the Effects of Physical Activity for Type 1 Diabetes: An In Silico Study. ( 30458503 )
2019
Sources

Variations for Diabetes Mellitus

About this section

ClinVar genetic disease variations for Diabetes Mellitus:

6 (show all 18)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNJ11 NM_000525.3(KCNJ11): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic rs80356625 GRCh37 Chromosome 11, 17409038: 17409038
2 KCNJ11 NM_000525.3(KCNJ11): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic rs80356625 GRCh38 Chromosome 11, 17387491: 17387491
3 KCNJ11 NM_000525.3(KCNJ11): c.964G> A (p.Glu322Lys) single nucleotide variant Pathogenic rs193929355 GRCh37 Chromosome 11, 17408675: 17408675
4 KCNJ11 NM_000525.3(KCNJ11): c.964G> A (p.Glu322Lys) single nucleotide variant Pathogenic rs193929355 GRCh38 Chromosome 11, 17387128: 17387128
5 ABCC8 NM_000352.4(ABCC8): c.1562G> A (p.Arg521Gln) single nucleotide variant Uncertain significance rs368114790 GRCh37 Chromosome 11, 17464335: 17464335
6 ABCC8 NM_000352.4(ABCC8): c.1562G> A (p.Arg521Gln) single nucleotide variant Uncertain significance rs368114790 GRCh38 Chromosome 11, 17442788: 17442788
7 KCNJ11 NM_000525.3(KCNJ11): c.988T> C (p.Tyr330His) single nucleotide variant Pathogenic rs587783675 GRCh37 Chromosome 11, 17408651: 17408651
8 KCNJ11 NM_000525.3(KCNJ11): c.988T> C (p.Tyr330His) single nucleotide variant Pathogenic rs587783675 GRCh38 Chromosome 11, 17387104: 17387104
9 KCNJ11 NM_000525.3(KCNJ11): c.685G> A (p.Glu229Lys) single nucleotide variant Pathogenic rs587783673 GRCh37 Chromosome 11, 17408954: 17408954
10 KCNJ11 NM_000525.3(KCNJ11): c.685G> A (p.Glu229Lys) single nucleotide variant Pathogenic rs587783673 GRCh38 Chromosome 11, 17387407: 17387407
11 KCNJ11 NM_000525.3(KCNJ11): c.679G> A (p.Glu227Lys) single nucleotide variant Pathogenic rs587783672 GRCh37 Chromosome 11, 17408960: 17408960
12 KCNJ11 NM_000525.3(KCNJ11): c.679G> A (p.Glu227Lys) single nucleotide variant Pathogenic rs587783672 GRCh38 Chromosome 11, 17387413: 17387413
13 KCNJ11 NM_000525.3(KCNJ11): c.498C> G (p.Cys166Trp) single nucleotide variant Likely pathogenic rs587783669 GRCh37 Chromosome 11, 17409141: 17409141
14 KCNJ11 NM_000525.3(KCNJ11): c.498C> G (p.Cys166Trp) single nucleotide variant Likely pathogenic rs587783669 GRCh38 Chromosome 11, 17387594: 17387594
15 KCNJ11 NM_000525.3(KCNJ11): c.463G> A (p.Val155Met) single nucleotide variant Uncertain significance rs587783668 GRCh37 Chromosome 11, 17409176: 17409176
16 KCNJ11 NM_000525.3(KCNJ11): c.463G> A (p.Val155Met) single nucleotide variant Uncertain significance rs587783668 GRCh38 Chromosome 11, 17387629: 17387629
17 MEN1 NM_000244.3(MEN1): c.669+1delG deletion Pathogenic rs1057518903 GRCh37 Chromosome 11, 64575362: 64575362
18 MEN1 NM_000244.3(MEN1): c.669+1delG deletion Pathogenic rs1057518903 GRCh38 Chromosome 11, 64807890: 64807890

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1b Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAM Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus
Sources

Expression for Diabetes Mellitus

About this section
Search GEO for disease gene expression data for Diabetes Mellitus.
Sources

Pathways for Diabetes Mellitus

About this section

Pathways related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 37
12.03 MIR145 MIR155 MIR30E MIR375 MIR99A
2
Parkinsons Disease Pathway 1
11.36 MIR132 MIR30E MIR375
3
Type II diabetes mellitus 37 1
Show member pathways
 11.24 ABCC8 HNF4A INS KCNJ11
4
FOXA2 and FOXA3 transcription factor networks 1
10.57 ABCC8 HNF4A INS KCNJ11
Sources

GO Terms for Diabetes Mellitus

About this section

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 INS MIR132 MIR134 MIR140 MIR155 MIR197
2 micro-ribonucleoprotein complex GO:0035068 9.32 MEG3 MIR132 MIR134 MIR140 MIR145 MIR155
3 inward rectifying potassium channel GO:0008282 9.16 ABCC8 KCNJ11

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 9.43 HNF4A MIR132 MIR155
2 positive regulation of endothelial cell apoptotic process GO:2000353 9.4 MIR132 MIR375
3 fatty acid homeostasis GO:0055089 9.37 INS MIR132
4 regulation of insulin secretion GO:0050796 9.33 ABCC8 HNF4A KCNJ11
5 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.32 ABCC8 MIR155
6 gene silencing by miRNA GO:0035195 9.32 MEG3 MIR132 MIR134 MIR140 MIR145 MIR155
7 miRNA mediated inhibition of translation GO:0035278 9.26 MIR132 MIR134 MIR145 MIR155

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP-activated inward rectifier potassium channel activity GO:0015272 9.16 ABCC8 KCNJ11
2 RNA polymerase II complex binding GO:0000993 9.13 MIR140 MIR145 MIR375
3 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR132 MIR134 MIR140 MIR145 MIR155 MIR30E
Sources

Sources for Diabetes Mellitus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....